PER

0.00%

10.0¢ percheron therapeutics limited

Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-147

First 147 Last

Share
Profile

Follow
itsagas

13,338 Posts.

1422

14/08/21

20:24

Post #: 55292171
Share

Originally posted by imperatore: ↑

Some food for thought:
- hold up since 2017 nothing done about it in 4 years.
- meeting with FDA unprepared as hold up always been there hanging over heads.
- apparently hold up was not mentioned during meeting even just for matter of enquire and/or if could
eventually be a problem…….very professional.
- FTD application sent and in my view without proper home work done……very professional
Mr. Diamond.
- After hinting from any corners of the world FTD was a given suddenly application withdrawn due to
hold up in dosing (remember it was there since 2017) and to be reapplied…..by when? In real time not
Diamond’s alleged deadlines.
- Latest announcement is as clear as mud (someone would say) and the Diamond instead of clarifying in
more understandable words let Dr. Gittleson to have a short sugar comment or an accountant that
instead of answering he redirect to the broker Morgan comments.
- As AKKI points out FTD has been granted to numerous bio products with less alleged “outstanding”
results but not to ATL1102……mystery.
I know that several posters think the Diamond is the best thing has happened to ANP but from the above
I really question his knowledge in scientific matters and by now since in my view time is running out also his ability to find funding. In other words it is imperative that Diamond comes out, put his face and give the share holders community some clear explanation (financial as well other application always mentioned but..?) and not the usual mmmm, hum, etc etc.
Will he do it or will keep hiding and buy time?

P.S. ITSA I don’t have any hidden agenda just ask the leader to do his job properly if he is able to otherwise move over.

Expand

Woke Imp….
you’ve never liked Diamond
but it’s the reason CG came on Board..
Understand this for the last time..
I met George and Mark in a Melbourne Pub 8 yrs ago..
They are a team.. George is a top notch Bio Scientist .. Patent lawyer…
None of us know what went on between FDA and Anp re application Fast Track…All I know it’s a work in progress

Imp:The FDA did not REJECT the Fast Track

FDA encouraged Anp to apply for FAST TRACK..

You are shitting in your own nest…

80% of long term holders on HC with credibility are happy with the ANP board ..

Morgans are happy with Anp Board

please let me know your Qualifications re Biotechs

ANP Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

The winners & losers on market if negative gearing were gone

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

There are more pages in this discussion • 28 more messages in this thread...

First 147 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $90.15M

Open	High	Low	Value	Volume
10.5¢	10.5¢	10.0¢	$47.27K	463.5K

Buyers (Bids)

No.	Vol.	Price($)
3	319942	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	86442	3

View Market Depth

No.	Vol.	Price($)
3	319942	0.100
3	113179	0.099
1	13000	0.098
2	130927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	86442	3
0.110	290000	4
0.115	601850	5
0.120	275642	8
0.125	65000	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

PER (ASX) Chart

Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-147

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-147

Top Stories

The winners & losers on market if negative gearing were gone

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Zeta Resources seeks to resolve the Panoramic takeover story

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News